Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQUARIUS: Immunotherapy With or Without Chemotherapy in Unresectable Stage III NSCLC Undergoing Concurrent Chemoradiotherapy
2025-523599-21-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of rilvegostomig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability. Planned start Jun 2026; status: authorised.
02
Drugs
rilvegostomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-523599-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523599-21-00.